Shortly after Amgen Inc. walked away from its partnership with Kyowa Kirin Co. Ltd., the Tokyo-based company said it is discontinuing all ongoing clinical trials for rocatinlimab due to safety concerns.
The U.S. FDA clearance Feb. 20 of East Windsor, N.J.-based Acrotech Biopharma Inc.’s PDE4 inhibitor Adquey (difamilast ointment 1%) for mild to moderate atopic dermatitis brought renewed focus on the mechanism, where other drugs are already approved and more are stocking developers’ pipelines across indications.
Researchers from Shanghai Ailux Biotechnology Co. Ltd. have disclosed preclinical data regarding their humanized bispecific antibody ALX-001 targeting TL1A and IL-23 for the potential treatment of immune-mediated inflammatory diseases (IMIDs).
After 118 years as a private company, dermatology specialist Leo Pharma A/S is poised to complete an IPO after reporting a full-year net profit for the first time since 2018.
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some signaling pathways are well defined in HS, the role of TNF-like ligand 1 (TL1A) is not well understood. A group of researchers has investigated the association of TL1A with HS, as well as its association with other cytokine networks.
Vidac Pharma Holding plc has announced the initiation of an in vivo preclinical program to evaluate the potential of its hexokinase 2 (HK2)/voltage-dependent anion channel (VDAC)-targeting approach in psoriasis.
Marking an important day for those with atopic dermatitis, shares of two biopharmas surged on clinical data suggesting new biologics are on their way to help address 40% of patients with uncontrolled disease.
Almirall SA has submitted a CTA filing for a bispecific antibody targeting IL-13 and OX-40L for the treatment of atopic dermatitis. The company expects to initiate a first-in-human phase I trial during the first half of this year.
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in disease activity, thus there is a need for novel medications.
RSS
